A niche market?....It is a drug therapy. If someone's life is at stake, why haven't they generated any domestic sales. Because the drug is the third option, when all other therapies have failed. Therefore it targets a very limited market, is not a cure, is extremely costly, and has very serious adverse and potentially fatal side effects. The drug has been available to physicians for 9 months. A partner is not the issue. Demand is just not there. As far as their pipeline goes, nothing can be expected near term. At a $38M burn rate per quarter, they will have to further dilute the stock to continue operations. Why do you think stock is at or near 52 week low? Even this news did not move the stock much.
News 
Market Data 
Discover 
AI
